Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anaprazole sodium PK study in hepatic/renal impairment and elderly
NCT07345689Phase 4Not yet recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of anaprazole sodium in gastroesophageal reflux disease (GERD), Peptic ulcer disease (PUD), sponsored by Xuanzhu Biopharmaceutical. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
anaprazole sodium
03
Conditions
gastroesophageal reflux disease (GERD)Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT07345689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345689.